Moreover, the inhibition of AChE is currently the most established approach for the management of AD, and numerous AChE inhibitors (AChEI) are used to attenuate the symptoms associated with this disease (such as tacrine, donzepil, and galanthamine) as reported by Orhan, Kartal, Tosun, and Sener (2007). The gene discussed is ACHE; the disease is Alzheimer disease.